TITLE

PERIPHERAL T-CELL LYMPHOMA, UNSPECIFIED - THE ANALYSIS OF THE DATA FROM THE CZECH LYMPHOMA STUDY GROUP (CLSG) REGISTRY

AUTHOR(S)
Prochazka, Vit; Trneny, Marek; Pytlik, Robert; Vasova, Ingrid; Kral, Zdenek; Belada, David; Kozak, Tomas; Kubackova, Katerina; Siffnerova, Hana; Matuska, Milan; Lysy, Milan; Bolomska, Inge; Petrakova, Katarina; Otavova, Barbora; Pribylova, Jana; Svecova, Jirina; Papajik, Tomas; Hamouzova, Michaela; Petrova, Marketa; Zapletalova, Jana
PUB. DATE
June 2007
SOURCE
Biomedical Papers of the Medical Faculty of Palacky University i;2007, Vol. 151 Issue 1, p103
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Peripheral T-cell lymphoma, unspecified (PTCL-US) is one of the entities from the infrequent family of nodal mature T-cell lymphomas. The clinical course is aggressive, and despite multiagent chemotherapy, the median survival is about 2 years. Published data are limited to restrospective, mostly single-center studies or reviews and usually include more lymphoma subtypes. Aim: To evaluate the current treatment modalities, clinical outcome and prognostic factors in unselected, new diagnosed patients with PTCL-US in the population of the central european region (Czech Republic). Method: Czech Lymphoma Study Group is a national scientific organization which provides an on-line database registry which collects a data about almost all new diagnosed lymphoma patients since year 2000. All diagnostic biopsies were reviewed by a reference pathologist. Results: We analyzed 63 patients with new diagnosis of PTCL-US. The median age was 59 years (25-81), chemotherapy (CHT) was administered in 56 of the 63 patients: anthracyclin-based CHT in 51 %, intensive CHT in 21 % and non-anthracyclin regimen was applied in 13 % of the patients. The overall response rate was 74.4 %, (CR in 57.4 %). After a median follow-up of 19.6 months, 41 % of the patients were in CR, 3.4 % in PR or stable disease and 55 % of the patients died. The estimated survival probability in 3 years was 36 %. Clinical stage (IV) and CR achievement were found to be independent survival predictors in a multivariate analysis. Conclusions: Although the current treatment modalities are mostly ineffective in PTCL-US, appropriate intesive treatment may lead to prolonged remission but not survival.
ACCESSION #
31371738

 

Related Articles

  • Spontaneous remission and relapse in adult T cell lymphoma/leukaemia associated with HTLV-I. Mattock, C.; Anderson, N.A.B.; Sheldon, C.D.; Rustin, M.H.A.; Hoffbrand, B.I. // British Medical Journal (Clinical Research Edition);5/3/1986, Vol. 292 Issue 6529, p1171 

    Examines the development of adult T cell leukemia in patient with lymphomatous skin infiltrate following a spontaneous remission. Failure of the patient to attend for a Kveim test; Performance of elective pyeloplasty on the patient; Complications in cytopenias by recurrent fungal infection.

  • Comparison of clinical outcome after autologous stem cell transplantation between patients with peripheral T-cell lymphomas and diffuse large B-cell lymphoma. Sohn, B. S.; Park, I.; Kim, E. K.; Yoon, D. H.; Lee, S. S.; Kang, B. W.; Jang, G.; Choi, Y. H.; Kim, C.; Lee, D. H.; Kim, S.; Huh, J.; Suh, C. // Bone Marrow Transplantation;Sep2009, Vol. 44 Issue 5, p287 

    Although patients with T-cell phenotype lymphomas are generally accepted to have worse prognosis than B-cell phenotype lymphomas, the studies comparing outcomes after autologous stem cell transplantation (ASCT) between peripheral T-cell lymphomas (PTCLs) and with diffuse large B-cell lymphoma...

  • Mucosal endocrine cell micronests and single endocrine cells following neo-adjuvant therapy for adenocarcinoma of the distal oesophagus and oesophagogastric junction. Stewart, Colin J. R.; Hillery, Simon // Journal of Clinical Pathology;Nov2007, Vol. 60 Issue 11, p1284 

    Aims: To determine the frequency of endocrine cell micronests (ECM) and single endocrine cells (SEC) within the glandular mucosa of the distal oesophagus and oesophagogastric junction (OGJ) following neo-adjuvant therapy for adenocarcinoma. Methods: The resection specimens from 11 patients with...

  • ADULT T-CELL LEUKEMIA/LYMPHOMA. TAKATSUKI, Kiyoshi // Leukemia (08876924);Apr97 Supplement 3, Vol. 11, p54 

    Aduli T-cell leukemia (ATL) was first reported in Japan, where it has a high incidence in the southwestern region. The retrovirus, human T-lymphotropic virus type I (HTLV-I), is the causative agent of ATL. In ATL-endemic areas, the rate of HTLV-I carriers is high. A definite diagnosis of ATL is...

  • Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma. Li Wang; Wen-Yu Shi; Zhi-Yuan Wu; Mariana Varna; Ai-Hua Wang; Li Zhou; Li Chen; Zhi-Xiang Shen; He Lu; Wei-Li Zhao; Anne Janin // Journal of Hematology & Oncology;2010, Vol. 3, p30 

    Mantle cell lymphoma (MCL) is a rare and aggressive type of B-cell non-Hodgkin's lymphoma. Patients become progressively refractory to conventional chemotherapy, and their prognosis is poor. However, a 38% remission rate has been recently reported in refractory MCL treated with temsirolimus, a...

  • Increased spontaneous apoptosis, but not survivin expression, is associated with histomorphologic response to neoadjuvant chemoradiation in rectal cancer. McDowell, Dermot T.; Smith, Fraser M.; Reynolds, John V.; Maher, Stephen G.; Adida, Collette; Crotty, Paul; Gaffney, Eoin F.; Hollywood, Donal; Mehigan, Brian; Stephens, Richard B.; Kennedy, M. J. // International Journal of Colorectal Disease;Nov2009, Vol. 24 Issue 11, p1261 

    Survivin has been shown to be an important mediator of cellular radioresistance in vitro. This study aims to compare survivin expression and apoptosis to histomorphologic responses to neoadjuvant radiochemotherapy (RCT) in rectal cancer. Thirty-six pre-treatment biopsies were studied. Survivin...

  • A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hermine, Olivier; Allard, Isabelle; Lévy, Vincent; Arnulf, Bertrand; Gessain, Antoine; Bazarbachi, Ali // Hematology Journal;2002, Vol. 3 Issue 6, p276 

    Adult T-cell leukemia/lymphoma ATL is an aggressive T cells malignancy, with poor prognosis due to chemotherapy resistance. Preliminary results using zidovudine (AZT) and interferon-α (IFN) showed high response rate in ATL patients. We report a prospective phase II trial using AZT/IFN...

  • Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favorable histological type. Lister, T.A.; Cullen, M.H.; Beard, M.E.J.; Brearly, R.L.; Whitehouse, J.M.A.; Wrigley, P.F.M.; Stansfeld, A.G.; Sutcliffe, S.B.J.; Malpas, J.S.; Crowther, D. // British Medical Journal;3/4/78, Vol. 1 Issue 6112, p533 

    Sixty-six untreated patients with advanced non-Hodgkin's lymphoma of favourable histological type were allocated alternately to initial treatment with cyclophosphamide, vincristine, and prednisolone or with chlorambucil. The complete remission rate was higher in the group receiving combination...

  • Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. Italiano, A.; Toulmonde, M.; Cioffi, A.; Penel, N.; Isambert, N.; Bompas, E.; Duffaud, F.; Patrikidou, A.; Lortal, B.; Le Cesne, A.; Blay, J.-Y.; Maki, R. G.; Schwartz, G. K.; Antonescu, C. R.; Singer, S.; Coindre, J.-M.; Bui, B. // Annals of Oncology;Jun2012, Vol. 23 Issue 6, p1601 

    Background: Data regarding the role of systemic therapy in patients with advanced well-differentiated/dedifferentiated liposarcomas (WDLPS/DDLPS) are limited. Methods: From 2000 to 2010, 208 patients with advanced WDLPS/DDLPS received chemotherapy in 11 participating institutions. Clinical and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics